Living with ulcerative colitis (UC) can be complicated. Explaining how you’re feeling in detail and what symptoms you’re experiencing can help you manage the condition. When you have an ...

Ulcerative colitis (UC) is a type of inflammatory bowel ... researchers are investigating the connection between dietary ...

Have you ever found yourself in a situation where, despite your best efforts, your Ulcerative Colitis (UC) symptoms flare up unexpectedly? UC, a chronic inflammatory bowel disease, can be ...

Ulcerative colitis is a type of chronic inflammatory bowel disease that causes painful ulcers and irritation in the large intestine. In North America alone, it is estimated to affect more than ...

If you’re facing a new diagnosis or flare up of ulcerative colitis (UC), losing someone ... “It hurts most if you have established patterns,” says Leah LeFebvre, PHD, assistant professor ...

Following the study, the FDA approved the use of Tremfya to treat moderately to severely active ulcerative colitis. In September 2024, the University of Chicago Medicine became the first hospital in ...

Appendectomy may be a useful addition to medical therapy for preventing relapse of ulcerative colitis among patients in ...

Reuters, the news and media division of Thomson Reuters, is the world’s largest multimedia news provider, reaching billions of people worldwide every day. Reuters provides business, financial, ...

researchers have identified protein patterns that separate healthy individuals from those that go on to develop Crohn's disease or ulcerative colitis. The results show that a specific combination ...

Although the appendix is generally believed to be a vestigial organ, there is growing evidence pointing to its possible role in modulating gut immunity and microbial homoeostasis.1,2 These roles have ...

Citation: Epstein-Barr virus aggravates ulcerative colitis via macrophage pyroptosis: Findings could yield new therapeutic target (2025, March 24) retrieved 20 April 2025 from https ...

Clinical Remission: Achieved in 33% of PL8177-treated patients versus 0% on placebo after eight weeks of treatment. Clinical Response (statistically significant): Demonstrated in 78% of PL8177 ...